N-alkoxyamide Conjugates for Atherosclerotic Lesion Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiotracers for imaging atherosclerosis have poor target/background and target/blood ratios, making them inadequate for non-invasive diagnosis and monitoring of coronary or carotid lesions, and there is a need for a method to detect and monitor the progression of cardiovascular diseases effectively.
Innovation Solution
Development of compounds with specific chelator moieties that can bind imaging agents, such as paramagnetic metal ions or radioisotopes, to enhance diagnostic imaging of atherosclerotic lesions and related cardiovascular conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiolabeled proteins and platelets are used as imaging agents, then some clinical potential is achieved, but poor target/background and target/blood ratios limit their effectiveness
Solution Approach 1:
The patent modifies the molecular parameters of imaging agents by using radiolabeled peptides with specific amino acid sequences that selectively bind to atherosclerotic lesion markers, thereby improving target/background ratios while maintaining clinical potential
Solution Approach 2:
The invention combines radiolabeled peptides with specific chelating agents and targeting moieties to create composite imaging agents that simultaneously achieve high target specificity, improved background contrast, and stable radioisotope binding
2Adaptability or versatility
If radiolabeled peptides and antibody fragments are used, then new opportunities for nuclear scintigraphic techniques are offered, but a non-invasive method to diagnose and monitor cardiovascular diseases is still needed
Solution Approach 1:
The patent develops imaging agents with universal applicability across different cardiovascular disease types and imaging modalities, enabling both diagnostic imaging and disease monitoring through a single non-invasive methodology
Data Source
Figure 1
AI summary
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.